Skye Bioscience, Inc. (SKYE)
$1.90-$0.05 (-2.56%) Today
Latest SKYE Insider Trades
Andrew J. Schwab - DirectorOpen-market sale
Andrew J. Schwab - DirectorAndrew J. Schwab - DirectorAndrew J. Schwab - DirectorAndrew J. Schwab - DirectorAndrew J. Schwab - DirectorAndrew J. Schwab - DirectorAndrew J. Schwab - DirectorAndrew J. Schwab - DirectorSkye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 18 | 751,680 | $281K |
| Grant or award | 1 | 1,090,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
35 Form 4 filings on record, the earliest from Oct 30, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 45,090 | $3.04 | $17K | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 1,830 | $3.04 | $695 | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 253,080 | $3.04 | $96K | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 10,255 | $2.80 | $4K | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 409 | $2.80 | $143 | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 57,476 | $2.80 | $20K | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 1,159 | $2.56 | $371 | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 46 | $2.56 | $15 | |
| Andrew J. Schwab - Director | Open-market sale | Common Stock | 6,495 | $2.56 | $2K | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 45,090 | $3.04 | $17K | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 1,830 | $3.04 | $695 | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 253,080 | $3.04 | $96K | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 10,255 | $2.80 | $4K | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 409 | $2.80 | $143 | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 57,476 | $2.80 | $20K | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 1,159 | $2.56 | $371 | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 46 | $2.56 | $15 | |
| 5AM Partners VII, LLC - 10% Owner | Open-market sale | Common Stock | 6,495 | $2.56 | $2K | |
| Punit Dhillon - Officer | Grant or award | Common Stock | 1,090,000 | $0.00 | - | |
| Karen L. Smith - Director | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 17,004 | - | - | |
| Christopher Twitty - Officer | Derivative | Stock Option (Right to Buy) | 17,004 | - | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | - | - | |
| Christopher Twitty - Officer | Derivative | Stock Option (Right to Buy) | 200,000 | - | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | - | - | |
| Christopher Twitty - Officer | Derivative | Stock Option (Right to Buy) | 75,000 | - | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 7,100 | - | - | |
| Christopher Twitty - Officer | Derivative | Stock Option (Right to Buy) | 7,100 | - | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | - | - | |
| Christopher Twitty - Officer | Derivative | Stock Option (Right to Buy) | 150,000 | - | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 12,000 | - | - | |
| Christopher Twitty - Officer | Derivative | Stock Option (Right to Buy) | 12,000 | - | - | |
| Annalisa Jenkins - Director | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Deborah H. Charych - Director | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Paul A. Grayson - Director | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Andrew J. Schwab - Director | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 150,000 | - | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 9,194 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 9,194 | - | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 22,021 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 22,021 | - | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 125,000 | - | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 8,000 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 8,000 | - | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 7,080 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 7,080 | - | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | - | - | |
| Tuan Tu Diep - Officer | Derivative | Stock Option (Right to Buy) | 75,000 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 250,000 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 250,000 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 36,000 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 36,000 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 12,360 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 12,360 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 650,000 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 650,000 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 125,000 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 9,013 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 9,013 | - | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 21,586 | - | - | |
| Punit Dhillon - Officer | Derivative | Stock Option (Right to Buy) | 21,586 | - | - | |
| Andrew J. Schwab - Director | Grant or award | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Paul A. Grayson - Director | Grant or award | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Karen L. Smith - Director | Grant or award | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Kaitlyn Arsenault - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Christopher Twitty - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Deborah H. Charych - Director | Grant or award | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Annalisa Jenkins - Director | Grant or award | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Puneet S. Arora - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 280,000 | $0.00 | - | |
| Andrew J. Schwab | Open-market sale | Common Stock | 58,642 | $28.56 | $209K | |
| Andrew J. Schwab | Open-market sale | Common Stock | 2,314 | $28.56 | $8K | |
| Andrew J. Schwab | Open-market sale | Common Stock | 163,979 | $27.36 | $561K | |
| Andrew J. Schwab | Open-market sale | Common Stock | 6,470 | $27.36 | $22K | |
| 5AM Partners VII, LLC | Open-market sale | Common Stock | 58,642 | $28.56 | $209K | |
| 5AM Partners VII, LLC | Open-market sale | Common Stock | 2,314 | $28.56 | $8K | |
| 5AM Partners VII, LLC | Open-market sale | Common Stock | 163,979 | $27.36 | $561K | |
| 5AM Partners VII, LLC | Open-market sale | Common Stock | 6,470 | $27.36 | $22K | |
| Tuan Tu Diep - Officer | Open-market sale | Common Stock | 85 | $44.40 | $472 | |
| Tuan Tu Diep - Officer | Open-market sale | Common Stock | 19,489 | $39.92 | $97K | |
| Punit Dhillon - Officer | Open-market sale | Common Stock | 364 | $44.40 | $2K | |
| Punit Dhillon - Officer | Open-market sale | Common Stock | 82,546 | $39.92 | $412K | |
| Paul A. Grayson - Director | Open-market sale | Common Stock | 307 | $44.40 | $2K | |
| Paul A. Grayson - Director | Open-market sale | Common Stock | 86,244 | $39.92 | $430K | |
| Kaitlyn Arsenault - Officer | Open-market sale | Common Stock | 190 | $44.40 | $1K | |
| Kaitlyn Arsenault - Officer | Open-market sale | Common Stock | 43,206 | $39.92 | $216K | |
| Annalisa Jenkins - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Kaitlyn Arsenault - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Andrew J. Schwab - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - |
Skye Bioscience, Inc. (SKYE) had 3 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for SKYE runs to 35 Form 4 filings, the earliest from 2024-10-30. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SKYE were filed in the last 90 days.
18 insider sales of SKYE were filed in the last 90 days, totaling $281K.
This page tracks SKYE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SKYE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
